Valuation : Immunovia AB

Market Cap 89.33M 9.28M 8.01M 7.55M 6.87M 12.85M 877M 12.95M 34.67M 448M 34.86M 34.1M 1.47B P/E 2026 *
-1.33x
P/E 2027 * -3.32x
Enterprise Value 54.33M 5.65M 4.87M 4.59M 4.18M 7.82M 533M 7.87M 21.09M 273M 21.2M 20.74M 896M EV / Sales 2026 *
17x
EV / Sales 2027 * 3.43x
Free-Float
90.23%
Yield 2026 *
-
Yield 2027 * -
1 day-0.60%
1 week-7.43%
Current month-6.25%
1 month-28.65%
3 months-34.00%
6 months-27.47%
Current year-41.85%
1 week 0.13
Extreme 0.127
0.14
1 month 0.13
Extreme 0.127
0.19
Current year 0.13
Extreme 0.127
0.25
1 year 0.13
Extreme 0.127
0.76
3 years 0.13
Extreme 0.127
4.73
5 years 0.13
Extreme 0.127
141.5
10 years 0.13
Extreme 0.127
298.5
Manager TitleAgeSince
Chief Executive Officer 53 29/04/2023
Chief Tech/Sci/R&D Officer 55 29/04/2024
Chief Tech/Sci/R&D Officer 54 31/01/2024
Director TitleAgeSince
Director/Board Member 72 09/12/2016
Chairman 69 26/05/2023
Director/Board Member 51 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/22 Buy

Chief Executive Officer

150,000 0.6628%
24/05/22 Buy

Chief Executive Officer

100,000 0.4419%
21/05/22 Buy

Chief Executive Officer

100,000 0.4419%
Change 5-day change 1-year change 3-year change Capi.($)
-0.60%-7.43%-81.97%-82.31% 9.28M
-0.53%-1.80%+25.46%-33.88% 17.63B
+0.94%-5.09%-34.93%+56.33% 1.61B
+0.71%-2.20%-23.16%+17.00% 925M
+1.45%-6.44%-50.62%-83.32% 957M
0.00%-0.05%+59.22%-7.37% 778M
-1.30%-1.30%-32.80%-46.48% 681M
-0.92%+9.97%-38.45%-46.70% 606M
+0.19%+6.59%-31.93%-33.02% 490M
-3.00%-0.39%+73.91%+45.29% 427M
Average -0.29%-0.40%-13.53%-21.45% 2.41B
Weighted average by Cap. -0.17%+0.23%+14.03%-26.29%

Financials

2026 *2027 *
Net sales 3.2M 333K 287K 270K 246K 460K 31.42M 464K 1.24M 16.06M 1.25M 1.22M 52.77M 17.3M 1.8M 1.55M 1.46M 1.33M 2.49M 170M 2.51M 6.71M 86.84M 6.75M 6.6M 285M
Net income -87M -9.04M -7.8M -7.35M -6.7M -12.51M -854M -12.61M -33.76M -437M -33.95M -33.21M -1.43B -76M -7.9M -6.81M -6.42M -5.85M -10.93M -746M -11.01M -29.5M -382M -29.66M -29.01M -1.25B
Net Debt -35M -3.64M -3.14M -2.96M -2.69M -5.03M -344M -5.07M -13.58M -176M -13.66M -13.36M -577M -30M -3.12M -2.69M -2.53M -2.31M -4.32M -295M -4.35M -11.64M -151M -11.71M -11.45M -495M
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
18
Date Price Change Volume
03/09/26 SEK 0.1320 -0.60% 568,774
02/09/26 SEK 0.1328 +0.61% 1,618,822
01/09/26 SEK 0.1320 -6.25% 6,401,112
31/08/26 SEK 0.1408 -1.26% 1,838,702
28/08/26 SEK 0.1426 0.00% 3,360,820

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMNOV Stock